全文获取类型
收费全文 | 8460篇 |
免费 | 383篇 |
国内免费 | 33篇 |
专业分类
耳鼻咽喉 | 157篇 |
儿科学 | 196篇 |
妇产科学 | 317篇 |
基础医学 | 1648篇 |
口腔科学 | 189篇 |
临床医学 | 617篇 |
内科学 | 1513篇 |
皮肤病学 | 160篇 |
神经病学 | 625篇 |
特种医学 | 538篇 |
外国民族医学 | 1篇 |
外科学 | 1545篇 |
综合类 | 136篇 |
一般理论 | 2篇 |
预防医学 | 240篇 |
眼科学 | 209篇 |
药学 | 394篇 |
中国医学 | 8篇 |
肿瘤学 | 381篇 |
出版年
2022年 | 42篇 |
2021年 | 104篇 |
2020年 | 50篇 |
2019年 | 99篇 |
2018年 | 109篇 |
2017年 | 103篇 |
2016年 | 130篇 |
2015年 | 160篇 |
2014年 | 178篇 |
2013年 | 251篇 |
2012年 | 387篇 |
2011年 | 419篇 |
2010年 | 263篇 |
2009年 | 252篇 |
2008年 | 421篇 |
2007年 | 418篇 |
2006年 | 398篇 |
2005年 | 445篇 |
2004年 | 416篇 |
2003年 | 402篇 |
2002年 | 384篇 |
2001年 | 190篇 |
2000年 | 142篇 |
1999年 | 149篇 |
1998年 | 106篇 |
1997年 | 102篇 |
1996年 | 98篇 |
1995年 | 83篇 |
1994年 | 67篇 |
1993年 | 54篇 |
1992年 | 51篇 |
1991年 | 80篇 |
1990年 | 60篇 |
1989年 | 66篇 |
1988年 | 80篇 |
1987年 | 65篇 |
1986年 | 61篇 |
1985年 | 69篇 |
1984年 | 50篇 |
1983年 | 42篇 |
1982年 | 66篇 |
1980年 | 49篇 |
1977年 | 52篇 |
1976年 | 50篇 |
1975年 | 49篇 |
1974年 | 51篇 |
1973年 | 50篇 |
1937年 | 38篇 |
1931年 | 38篇 |
1926年 | 38篇 |
排序方式: 共有8876条查询结果,搜索用时 15 毫秒
81.
Pham MT Maitz MF Reuther H Muecklich A Prokert F Steiner G 《Journal of biomedical materials research. Part A》2004,71(1):16-24
The native extracellular matrix (ECM) laid down on silicon and titanium surfaces by osteoblast-like SAOS-2 cells was exposed by selective removal of cells. This type of material surface ECM-Si, ECM-Ti was shown to promote the nucleation of calcium phosphate from a simulated body fluid (SBF). Microscopic and spectroscopic results revealed the effect was associated with a collagen fiber-free extracellular matrix. 相似文献
82.
Horak F Stübner UP Zieglmayer R Harris AG 《The Journal of allergy and clinical immunology》2002,109(6):956-961
BACKGROUND: Unlike many antihistamines, desloratadine can reduce nasal congestion in patients with seasonal allergic rhinitis (SAR). OBJECTIVE: We compared the effects of 5 mg of desloratadine and placebo on nasal airflow and SAR symptoms, including nasal congestion, in response to grass pollen in an allergen-exposure unit. METHODS: In a randomized, double-blind, placebo-controlled, crossover trial, 47 subjects with histories of SAR received desloratadine or placebo every morning for 7 days and, after a 10-day washout period, were crossed over to the other treatment arm for 7 days. Subjects underwent a 6-hour allergen exposure on day 7 of each treatment period. Nasal airflow and nasal secretion weights were measured before and every 30 minutes during allergen exposure; SAR symptoms (including nasal congestion) were scored before exposure and every 15 minutes thereafter. RESULTS: Nasal obstruction, as measured by nasal airflow, was less severe with desloratadine than with placebo (P <.02). Individual and combined SAR symptom severity scores, including nasal congestion and sneezing, were significantly lower with desloratadine than with placebo (all P < or =.003). Within 30 minutes of allergen exposure, less severely decreased nasal airflow (P <.02), less nasal secretions (P <.001), and less severe symptoms, including nasal congestion (P <.002), rhinorrhea, and sneezing, occurred with desloratadine compared with placebo, and this continued throughout (0-6 hours) allergen exposure. Desloratadine was well tolerated, with an adverse event profile similar to that of placebo. CONCLUSION: In subjects with allergen-induced SAR symptoms, desloratadine significantly reduced the severity of nasal obstruction and accompanying complaints of nasal congestion and other SAR symptoms compared with the effects of placebo. 相似文献
83.
Charles Frèche Francisque Leynadier Friedrich Horak David Hide Fernando Duce Gracia Manfred Goos Claus Bachert Attila Horvath Eva Antosova Muriel Verrecchia Paul Ben Soussen 《Annals of allergy, asthma & immunology》2002,89(3):304-310
BACKGROUND: Mizolastine is a nonsedating H1 histamine receptor antagonist with additional antiallergic properties currently marketed in Europe for the treatment of seasonal and perennial allergic rhinitis (PAR) and urticaria. OBJECTIVE: This multicenter, randomized, double-blind, parallel-group study was conducted to evaluate the efficacy and safety of mizolastine in PAR compared with loratadine and placebo. METHODS: After a 1-week placebo run-in period, 428 adult PAR patients received placebo (146 of 428), mizolastine 10 mg (141 of 428), or loratadine 10 mg (141 of 428) once daily for 28 days. Symptoms were evaluated by patients and physicians using a total nasal score, evaluating itching, rhinorrhea, nasal blockade, and sneezing severity. RESULTS: Mizolastine treatment resulted in a significantly greater decrease in patient-rated total nasal score than placebo after 2 weeks (D14; -42%, P < 0.001) and at the end of the treatment period (-46%, P = 0.01), and significantly greater than that observed with loratadine at D14 (P = 0.031). No significant difference in change in total nasal score was observed between loratadine and placebo at 2- and 4-week visits. The global safety was satisfactory and the incidence of adverse events was similar in the three treatment groups. CONCLUSIONS: Mizolastine provides effective symptom relief in PAR together with a satisfactory safety profile. Improvement with mizolastine was significantly greater than placebo throughout the study despite a large placebo effect. Also mizolastine's effects were greater those observed with loratadine after 2 weeks of treatment. 相似文献
84.
85.
86.
Henrik Ewald Ole Mors Tracey Flint Ursula Friedrich Hans Eiberg Torben A. Kruse 《American journal of medical genetics. Part A》1995,60(5):386-392
The long arm of chromosome 11 is one of the most interesting regions in the search for major genes involved in the etiology of manic-depressive illness. Several candidate genes have been identified, including the gene encoding the dopamine D2 receptor, the M1 muscarinic receptor, and porfobillinogen deaminase. Furthermore, different families with co-segregation of psychiatric illness and structural chromosome abnormalities involving regions 11q21, 11q22.3, and 11q25 have been reported. Using narrow as well as broad phenotypic models, conservative genetic parameters, models with dominant or recessive modes of inheritance, and various methods to reduce misclassification, the present study did not find evidence for a major gene causing manic-depressive illness on the long arm of chromosome 11. In the broader phenotypic models multi-point analyses excluded at least 11q14 to 11q23.3, approximately 60 cM, even in one large family. Assuming homogeneity close linkage to DRD2 was excluded for all dominant models, and also in the affecteds-only analyses in the large family alone. © 1995 Wiley-Liss, Inc. 相似文献
87.
Dou Q; Tarnuzzer RW; Williams RS; Schultz GS; Chegini N 《Molecular human reproduction》1997,3(11):1005-1014
88.
89.
90.